- Home
- BRNS vs REFR Comparison
BRNS vs REFR Comparison
Compare BRNS & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- REFR
- Stock Information
- Founded
- BRNS 2016
- REFR 1965
- Country
- BRNS United Kingdom
- REFR United States
- Employees
- BRNS N/A
- REFR N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- REFR Multi-Sector Companies
- Sector
- BRNS Health Care
- REFR Miscellaneous
- Exchange
- BRNS Nasdaq
- REFR Nasdaq
- Market Cap
- BRNS 58.0M
- REFR 51.8M
- IPO Year
- BRNS 2021
- REFR N/A
- Fundamental
- Price
- BRNS $1.61
- REFR $1.74
- Analyst Decision
- BRNS Strong Buy
- REFR
- Analyst Count
- BRNS 1
- REFR 0
- Target Price
- BRNS $3.00
- REFR N/A
- AVG Volume (30 Days)
- BRNS 248.2K
- REFR 48.7K
- Earning Date
- BRNS 11-05-2025
- REFR 11-06-2025
- Dividend Yield
- BRNS N/A
- REFR N/A
- EPS Growth
- BRNS N/A
- REFR N/A
- EPS
- BRNS N/A
- REFR N/A
- Revenue
- BRNS $14,969,000.00
- REFR $1,222,239.00
- Revenue This Year
- BRNS N/A
- REFR N/A
- Revenue Next Year
- BRNS N/A
- REFR N/A
- P/E Ratio
- BRNS N/A
- REFR N/A
- Revenue Growth
- BRNS 1766.46
- REFR N/A
- 52 Week Low
- BRNS $0.64
- REFR $0.93
- 52 Week High
- BRNS $2.92
- REFR $2.31
- Technical
- Relative Strength Index (RSI)
- BRNS 65.26
- REFR 65.88
- Support Level
- BRNS $1.36
- REFR $1.40
- Resistance Level
- BRNS $1.67
- REFR $1.63
- Average True Range (ATR)
- BRNS 0.17
- REFR 0.14
- MACD
- BRNS 0.05
- REFR 0.02
- Stochastic Oscillator
- BRNS 72.15
- REFR 96.51
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.